Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715024 | 1.00 | MAPT (0.68) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6724630 | 0.89 | ABCG2 (0.72) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6724627 | 0.89 | ABCG2 (0.72) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6717914 | 0.87 | ABCG2 (0.68) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6718799 | 0.87 | ABCG2 (0.55) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL31412221 | 0.87 | MAPT (0.64) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6718802 | 0.87 | ABCG2 (0.55) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29011937 | 0.87 | MAPT (0.67) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6714565 | 0.86 | PDE4A (0.69) | MAPTMEN1KMT2AABCG2TNFRSF1A | |
| SCHEMBL6718613 | 0.85 | MAPT (0.70) | MAPTNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | MAPT 1612/4885NPC1 3381/4885RAB9A 1699/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | MAPT 1920/4885NPC1 3772/4885RAB9A 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.